Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Double-Blind, Parallel Group Study Comparing the Bioequivalence of Teva Pharmaceuticals, USA's Generic Formulation of Metronidazole Vaginal Gel, 0.75% and MetroGel-Vaginal® Metronidazole Vaginal Gel, 0.75% in the Treatment of Bacterial Vaginosis

NCT01020396 is registered in ClinicalTrials.gov with Teva Pharmaceuticals USA as lead sponsor.

NCT NCT01020396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01020396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Double-Blind, Parallel Group Study Comparing the Bioequivalence of Teva Pharmaceuticals, USA's Generic Formulation of Metronidazole Vaginal Gel, 0.75% and MetroGel-Vaginal® Metronidazole Vaginal Gel, 0.75% in the Treatment of Bacterial Vaginosis
Lead sponsor
Teva Pharmaceuticals USA
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2002
Completion date
March 31, 2003
Enrollment
579 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial vaginosis